FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116943788> ?p ?o ?g. }

• W2116943788 endingPage "69" @default.
• W2116943788 startingPage "69" @default.
• W2116943788 abstract "The endothelin system is implicated in the pathogenesis of melanoma. We evaluated the effects of bosentan - a dual endothelin receptor antagonist - in patients receiving first-line dacarbazine therapy for stage IV metastatic cutaneous melanoma in a phase 2, proof-of-concept study. Eligible patients had metastatic cutaneous melanoma naïve to chemotherapy or immunotherapy, no central nervous system involvement, and serum lactate dehydrogenase <1.5 × upper limit of normal. Treatment comprised bosentan 500 mg twice daily or matching placebo, in addition to dacarbazine 1000 mg/m2 every three weeks. Eighty patients were randomized (double-blind) and 38 in each group received study treatment. Median time to tumor progression (primary endpoint) was not significantly different between the two groups (placebo, 2.8 months; bosentan, 1.6 months; bosentan/placebo hazard ratio, 1.144; 95% CI, 0.717-1.827; p = 0.5683). Incidences of most adverse events and clinically relevant increases in hepatic transaminases were similar between treatment groups although hemoglobin decrease to >8 and ≤ 10 g/dL and ≤ 8 g/dL was more common in the bosentan group. In patients receiving dacarbazine as first-line chemotherapy for metastatic melanoma, the addition of high-dose bosentan had no effect on time to tumor progression or other efficacy parameters. There were no unexpected safety findings. This study is registered in ClinicalTrials.gov under the unique identifier NCT01009177." @default.
• W2116943788 created "2016-06-24" @default.
• W2116943788 creator A5007161617 @default.
• W2116943788 creator A5042431934 @default.
• W2116943788 creator A5050782218 @default.
• W2116943788 creator A5055038393 @default.
• W2116943788 creator A5062978331 @default.
• W2116943788 creator A5063643274 @default.
• W2116943788 date "2010-01-01" @default.
• W2116943788 modified "2023-10-16" @default.
• W2116943788 title "A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy" @default.
• W2116943788 cites W1511251378 @default.
• W2116943788 cites W1591072050 @default.
• W2116943788 cites W1879616740 @default.
• W2116943788 cites W1917632054 @default.
• W2116943788 cites W1974227996 @default.
• W2116943788 cites W1985669197 @default.
• W2116943788 cites W2011852843 @default.
• W2116943788 cites W2020830322 @default.
• W2116943788 cites W2021191584 @default.
• W2116943788 cites W2027567030 @default.
• W2116943788 cites W2048443661 @default.
• W2116943788 cites W2100132196 @default.
• W2116943788 cites W2102344094 @default.
• W2116943788 cites W2105570450 @default.
• W2116943788 cites W2106787323 @default.
• W2116943788 cites W2109513968 @default.
• W2116943788 cites W2110429401 @default.
• W2116943788 cites W2114124586 @default.
• W2116943788 cites W2120807471 @default.
• W2116943788 cites W2131109593 @default.
• W2116943788 cites W2131365547 @default.
• W2116943788 cites W2137723371 @default.
• W2116943788 cites W2139248078 @default.
• W2116943788 cites W2139684524 @default.
• W2116943788 cites W2143132974 @default.
• W2116943788 cites W2145254726 @default.
• W2116943788 cites W2203317209 @default.
• W2116943788 cites W2323721668 @default.
• W2116943788 doi "https://doi.org/10.1186/1476-4598-9-69" @default.
• W2116943788 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2856553" @default.
• W2116943788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20350333" @default.
• W2116943788 hasPublicationYear "2010" @default.
• W2116943788 type Work @default.
• W2116943788 sameAs 2116943788 @default.
• W2116943788 citedByCount "40" @default.
• W2116943788 countsByYear W21169437882012 @default.
• W2116943788 countsByYear W21169437882013 @default.
• W2116943788 countsByYear W21169437882014 @default.
• W2116943788 countsByYear W21169437882015 @default.
• W2116943788 countsByYear W21169437882016 @default.
• W2116943788 countsByYear W21169437882017 @default.
• W2116943788 countsByYear W21169437882018 @default.
• W2116943788 countsByYear W21169437882019 @default.
• W2116943788 countsByYear W21169437882020 @default.
• W2116943788 countsByYear W21169437882021 @default.
• W2116943788 countsByYear W21169437882022 @default.
• W2116943788 crossrefType "journal-article" @default.
• W2116943788 hasAuthorship W2116943788A5007161617 @default.
• W2116943788 hasAuthorship W2116943788A5042431934 @default.
• W2116943788 hasAuthorship W2116943788A5050782218 @default.
• W2116943788 hasAuthorship W2116943788A5055038393 @default.
• W2116943788 hasAuthorship W2116943788A5062978331 @default.
• W2116943788 hasAuthorship W2116943788A5063643274 @default.
• W2116943788 hasBestOaLocation W21169437881 @default.
• W2116943788 hasConcept C126322002 @default.
• W2116943788 hasConcept C142724271 @default.
• W2116943788 hasConcept C143998085 @default.
• W2116943788 hasConcept C144980905 @default.
• W2116943788 hasConcept C168563851 @default.
• W2116943788 hasConcept C170493617 @default.
• W2116943788 hasConcept C197934379 @default.
• W2116943788 hasConcept C203092338 @default.
• W2116943788 hasConcept C204787440 @default.
• W2116943788 hasConcept C27081682 @default.
• W2116943788 hasConcept C2776345702 @default.
• W2116943788 hasConcept C2776694085 @default.
• W2116943788 hasConcept C2777482430 @default.
• W2116943788 hasConcept C2780964509 @default.
• W2116943788 hasConcept C2781109936 @default.
• W2116943788 hasConcept C71924100 @default.
• W2116943788 hasConcept C90924648 @default.
• W2116943788 hasConceptScore W2116943788C126322002 @default.
• W2116943788 hasConceptScore W2116943788C142724271 @default.
• W2116943788 hasConceptScore W2116943788C143998085 @default.
• W2116943788 hasConceptScore W2116943788C144980905 @default.
• W2116943788 hasConceptScore W2116943788C168563851 @default.
• W2116943788 hasConceptScore W2116943788C170493617 @default.
• W2116943788 hasConceptScore W2116943788C197934379 @default.
• W2116943788 hasConceptScore W2116943788C203092338 @default.
• W2116943788 hasConceptScore W2116943788C204787440 @default.
• W2116943788 hasConceptScore W2116943788C27081682 @default.
• W2116943788 hasConceptScore W2116943788C2776345702 @default.
• W2116943788 hasConceptScore W2116943788C2776694085 @default.
• W2116943788 hasConceptScore W2116943788C2777482430 @default.
• W2116943788 hasConceptScore W2116943788C2780964509 @default.
• W2116943788 hasConceptScore W2116943788C2781109936 @default.
• W2116943788 hasConceptScore W2116943788C71924100 @default.

• next